Researchers identify way to weaken malaria parasites against popular drug treatment

December 14, 2017

Indiana University School of Medicine researchers have identified a way to block the ability of parasites that cause malaria to shield themselves against drug treatments in infected mice--a finding that could lead to the development of new approaches to combat this deadly disease in humans.

Malaria continues to be one of the most devastating diseases in the world. According to the World Health Organization, nearly half of the world's population is at risk of malaria, and in 2015, there were roughly 212 million new cases of malaria, with an estimated 429,000 malaria-related deaths worldwide.

Malaria is caused by a single-celled parasite called Plasmodium that is transmitted during a mosquito bite. Plasmodium parasites have evolved resistance to key antimalarial medications traditionally used to fight the disease, which is why there is an urgent need to identify new treatment strategies.

Artemisinin is the active ingredient in the sweet wormwood bush that has been used for centuries as an antimalarial treatment in China. Today, artemisinin and its derivatives (known as ARTs) are among the most potent antimalarial medications used as the frontline treatment in more than 100 countries.

While ARTs can rapidly reduce the number of parasites in the blood, treatment with artemisinin fails for many patients because it appears that some parasites can enter a latent stage that allows them to ride out the presence of the drug. When patients finish their medication, these latent parasites reactivate and cause a relapse of the infection. This phenomenon is deemed a treatment failure, and it is emerging as a major clinical problem in battling malaria.

In a collaborative study published Dec. 13 in Cell Host & Microbe, a team of researchers led by Research Assistant Professor Min Zhang, PhD, of the IU School of Medicine Department of Pharmacology and Toxicology and the Department of Pediatrics, identified the molecular mechanism leading to ART treatment failures.

Their findings build on work initiated in the laboratory of Victor Nussenzweig, PhD, at New York University School of Medicine, where Dr. Zhang investigated whether the latency seen in malaria parasites treated with ART involves a stress pathway that regulates protein production. Professors William Sullivan, PhD, and Ronald Wek, PhD, at IU School of Medicine first connected this stress response pathway to parasite latency in their studies of a related parasite called Toxoplasma gondii.

According to Dr. Sullivan, who explains more in a blog post, the stress response pathway centers on a protein called eukaryotic translation initiation factor-2 (eIF2), which is responsible for starting protein synthesis. When a cell is stressed, eIF2 is chemically modified by eIF2 kinases, a special group of proteins that switch the types of proteins made in the cell.

Dr. Zhang discovered that ART treatment caused Plasmodium's eIF2 to be modified by a kinase called PK4. When PK4 was blocked either genetically or with a kinase-blocking drug, the parasites could no longer enter their latent stage when hit with ART--making the treatment more successful against malaria by preventing treatment failure.

"This is a wonderful example of basic research leading to new ways to combat deadly diseases such as malaria," said Dr. Sullivan, a corresponding author and senior investigator on the study. "Inhibition of this eIF2 kinase might solve the problem of latent infections caused by other clinically important parasites as well."
This research was funded by grants from the National Institutes of Health.

Indiana University

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to